PLACEBO-CONTROLLED TRIAL OF THE XANTHINE DERIVATIVE PROPENTOFYLLINE IN DEMENTIA

被引:19
作者
MOLLER, HJ [1 ]
MAURER, I [1 ]
SALETU, B [1 ]
机构
[1] UNIV VIENNA,DEPT PSYCHIAT,A-1010 VIENNA,AUSTRIA
关键词
D O I
10.1055/s-2007-1014297
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Treatment of dementing illnesses is still unsatisfactory and agents that might have potential for improving cognitive functions are therefore under extensive investigation. Over a 3-month period a multicenter, double-blind, placebo-controlled, parallel-group study was conducted in 190 patients with dementia to examine whether administration of the xanthine derivative propentofylline at 0.9 g/d might either improve cognition or slow the progression of the disease. Improvement in performance on the Gottfries-Brane-Steen scale (GBS) and in at least two of eight psychometric assessments were defined a priori as the primary efficacy measures. The total scores on the GBS decreased in both the propentofylline and the placebo groups, with improvement however being significantly (p < 0.0001) higher in the propentofylline group. The mean scores in the Mini-Mental State Examination increased significantly (p < 0.05) in both groups, but the increase was significantly (p < 0.02) higher in the propentofylline-treated group. In contrast, psychometric assessments and the cognitive difficulties scale failed to demonstrate a therapeutic benefit of propentofylline after three months. Performance in these categories showed a significant (p <0.05) improvement for the propentofylline-treated patients and for the placebo-treated patients, but was comparable for both groups. Thus, in spite of the positive results in GBS, the efficacy of propentofylline could not be established according to the definition of the primary efficacy measures. The clinical parameters, however, can be positively influenced by propentofylline. In addition, the results indicate that patient performance can already be enhanced if subjects are required to engage in cognitive tasks.
引用
收藏
页码:159 / 165
页数:7
相关论文
共 20 条
[1]   OXIRACETAM IN THE TREATMENT OF MULTI-INFARCT DEMENTIA [J].
BAUMEL, B ;
EISNER, L ;
KARUKIN, M ;
MACNAMARA, R ;
KATZ, RJ ;
DEVEAUGHGEISS, J .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1989, 13 (05) :673-682
[2]   COGNITIVE PERFORMANCE AND FUNCTIONAL COMPETENCE IN COEXISTING DEMENTIA AND DEPRESSION [J].
BREEN, AR ;
LARSON, EB ;
REIFLER, BV ;
VITALIANO, PP ;
LAWRENCE, GL .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1984, 32 (02) :132-137
[3]  
DAVIES A, 1968, J CLIN PSYCHOL, V24, P96
[4]   PROTECTION AGAINST ISCHEMIC BRAIN-DAMAGE USING PROPENTOFYLLINE IN GERBILS [J].
DELEO, J ;
SCHUBERT, P ;
KREUTZBERG, GW .
STROKE, 1988, 19 (12) :1535-1539
[5]   THE IMPACT OF MEMORY ON AGE-DIFFERENCES IN DIGIT SYMBOL PERFORMANCE [J].
ERBER, JT ;
BOTWINICK, J ;
STORANDT, M .
JOURNALS OF GERONTOLOGY, 1981, 36 (05) :586-590
[6]   VISUOPERCEPTUAL PROCESSES IN BRAIN-DAMAGED PATIENTS ON DIGIT SYMBOL SUBSTITUTION TEST [J].
GLOSSER, G ;
BUTTERS, N ;
KAPLAN, E .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1977, 7 (02) :59-66
[7]   CEREBROVASCULAR EFFECTS OF A XANTHINE DERIVATIVE PROPENTOFYLLINE (HWA 285) [J].
GROME, JJ ;
RUDOLPHI, K ;
HARPER, AM .
DRUG DEVELOPMENT RESEARCH, 1985, 5 (02) :111-121
[8]  
GROME JJ, 1985, ADENOSINE RECEPTORS, P453
[9]   THE EFFECT OF A XANTHINE DERIVATIVE, 1-(5'-OXOHEXYL)-3-METHYL-7-PROPYLXANTHINE (HWA-285), ON HEART PERFORMANCE AND REGIONAL BLOOD-FLOW IN DOGS AND RABBITS [J].
HUDLICKA, O ;
KOMAREK, J ;
WRIGHT, AJA .
BRITISH JOURNAL OF PHARMACOLOGY, 1981, 72 (04) :723-730
[10]  
LINDSEY BA, 1969, J CLIN PSYCHOL, V25, P156, DOI 10.1002/1097-4679(196904)25:2<156::AID-JCLP2270250211>3.0.CO